tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Edesa Biotech assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Yi Chen assumed coverage of Edesa Biotech (EDSA) with a Buy rating and $5 price target Edesa is a clinical stage biopharmaceutical company primarily focused on the development of novel treatments for dermatology and respiratory indications, the analyst tells investors in a research note. The firm says the company’s lead drug candidate EB06 has a favorable safety and tolerability profile for treating vitiligo.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1